MF59-Adjuvanted seasonal influenza vaccine including H1N1 leads to robust serological response rates in immunocompromised patients after liver and kidney transplantation
K Wursthorn, S Pischke, J Buchta, B Zacher, A Müller-Heine, A Großhennig, C Schröder, C Blume, T Ganten, CP Strassburg, A Koch, MP Manns · Zeitschrift für Gastroenterologie · 2012 · Heft 08
Bibliografische Angaben
Zusammenfassung
Background and aims: Influenza infection in solid-organ transplant recipients leads to increased morbidity and mortality. Vaccination is preventive despite lower efficacy with approved non-adjuvanted vaccines. The aim of this study was to evaluate the immunogenicity and safety of the MF59-adjuvanted influenza vaccine 2010/11 (Fluad®) in liver/kidney transplant recipients under immunosuppression compared to healthy subjects. Methods: 61 solid-organ transplant recipients (TX) and 61 age-matched healthy subjects (HC) received a single dose of Fluad® between November 2010 and May 2011at two sites. Achieving serologi…
